Table 1 Clinical characteristics of the study population during valsartan treatment
Baseline | 8 weeks | 24 weeks | Pa | Pb | |
|---|---|---|---|---|---|
Age (years) | 47.6 ± 12.5 | NA | NA | ||
Male | 105 (51.2) | NA | NA | ||
Comorbid disease | |||||
Hypertension | 80 (39.0) | NA | NA | ||
Diabetes mellitus | 39 (19.0) | NA | NA | ||
Mean arterial pressure (mmHg) | 111.6 ± 12.0 | 110.9 ± 15.3 | 110.4 ± 12.6 | 0.510 | 0.142 |
Blood sample | |||||
BUN (mg/dL) | 20.1 ± 7.83 | 20.4 ± 8.04 | 21.2 ± 9.39 | 0.388 | < 0.001 |
Serum creatinine (mg/dL) | 1.27 ± 0.46 | 1.30 ± 0.48 | 1.32 ± 0.53 | 0.001 | < 0.001 |
eGFR (mL/min/1.73m2) | 63.2 ± 28.8 | 61.0 ± 27.5 | 61.6 ± 29.7 | 0.003 | 0.009 |
Serum albumin (mg/dL) | 4.02 ± 0.45 | 4.04 ± 0.58 | 4.06 ± 0.58 | 0.193 | 0.301 |
Serum cholesterol (mg/dL) | 181.8 ± 35.6 | 180.4 ± 36.4 | 178.4 ± 33.9 | 0.429 | 0.245 |
Serum uric acid (mg/dL) | 6.91 ± 1.86 | 7.02 ± 1.88 | 6.94 ± 1.77 | 0.264 | 0.847 |
Urine sample | |||||
uPCR (mg/mg) | 1.85 (1.34–2.76) | 1.69 (0.99–2.57) | 1.40 (0.81–2.58) | < 0.001 | < 0.001 |
ln(UAGT/Cr) (ug/g) | 3.49 (2.73–4.31) | 3.36 (2.21–4.06) | 3.16 (2.17–4.26) | 0.079 | 0.005 |
ln(UR/Cr) (pg/g) | −1.14 (−2.08–0.62) | NA | NA | ||
uNa/Cr (mmol/mmol) | 11.4 (7.2–18.8) | 11.0 (6.8–17.5) | 11.7 (8.1–17.3) | 0.242 | 0.185 |